Cytovale Receives Additional BARDA Funding to Evaluate Rapid Sepsis Diagnostic in Persons Under Investigation (PUI) for COVID-19
Cytovale Receives Additional BARDA Funding to Evaluate Rapid Sepsis Diagnostic in Persons Under Investigation (PUI) for COVID-19
04/23/20, 12:36 PM
Location
san franciscoCytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, announced today the expansion of a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to conduct a pilot study for Cytovale’s Rapid Sepsis Diagnostic System for patients with potential respiratory infections, including those with SARS-CoV-2, responsible for COVID-19.
Company Info
Company
Cytovale
Location
san francisco, california, united states
Additional Info
Cytovale, based in San Francisco, Calif., is a medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning, and applying this first to sepsis, a condition whose early detection dramatically improves patient outcomes. For more information visit cytovale.com.